Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pembrolizumab with Bacillus Calmette-Guerin for treating high-risk non-muscle invasive bladder cancer Bacillus Calmette-Guerin (BCG; BCG Tokyo-172; OncoTICE) , Pembrolizumab (Keytruda; MK-3475) Bladder cancer Urological Cancer 2023 View  |  Download
Pembrolizumab with chemoradiotherapy for treating high-risk locally advanced cervical cancer Chemoradiotherapy , Pembrolizumab (Keytruda; MK-3475) Cervical cancer Female Reproductive Cancer 2022 View  |  Download
Pembrolizumab with chemotherapy for HR+/HER2- locally recurrent inoperable or metastatic breast cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Breast cancer Breast Cancer 2023 View  |  Download
Pembrolizumab with chemotherapy for platinum-resistant recurrent ovarian cancer after 1 or 2 therapies Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Ovarian cancer Female Reproductive Cancer 2023 View  |  Download
Pembrolizumab with chemotherapy for treating advanced or recurrent endometrial cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Pembrolizumab with Enzalutamide and androgen deprivation therapy for the treatment of metastatic hormone sensitive prostate cancer Androgen deprivation therapy , Enzalutamide (Xtandi; MDV3100) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Pembrolizumab with enzalutamide for treating
metastatic castration-resistant prostate cancer
Enzalutamide (Xtandi; MDV3100) , Pembrolizumab (Keytruda; MK-3475) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Pembrolizumab with Lenvatinib and chemotherapy for previously untreated advanced or metastatic gastroesophageal adenocarcinoma Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Gastroesophageal adenocarcinoma Gastrointestinal Cancer 2023 View  |  Download
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Colorectal cancer Gastroenterology , Oncology 2022 View  |  Download
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer Chemoradiotherapy , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
1 2 77 78 79 80 81 113 114
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications